# A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

> **NCT07502222** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 168 (estimated)

## Conditions studied

- Moderate-to-Severe Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** AK139 and placebo
- **BIOLOGICAL:** AK139
- **BIOLOGICAL:** AK139 and placebo
- **BIOLOGICAL:** AK139
- **BIOLOGICAL:** AK139 and placebo
- **BIOLOGICAL:** AK139 and placebo
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07502222
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2027-11
- **Final completion:** 2028-01-10
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502222, "A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07502222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*